CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC
Executive Summary
The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.